Evidence map›Paper›PMID 24661355›Full record

Trial reportBMC nephrology2014

Cardiovascular effects of cholecalciferol treatment in dialysis patients--a randomized controlled trial.

Frank H Mose, Henrik Vase, Thomas Larsen, Anne S P Kancir, Renata Kosierkiewic, Bartlomiej Jonczy, Annebirthe B Hansen, Anna E Oczachowska-Kulik, Ingrid M Thomsen, Jesper N Bech and 1 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC nephrology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01312714 (A Randomized, Placebo-Controlled, Double Blind Study Evaluating the Effect of Cholecalciferol on Vasoactive Hormones, Heart Function, Arterial Stiffness, and Blood Pressure in Dialysis Patients.), which is not on this map. Cited by 27 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 5 pooled it
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01312714 phase2completednot on this map

A Randomized, Placebo-Controlled, Double Blind Study Evaluating the Effect of Cholecalciferol on Vasoactive Hormones, Heart Function, Arterial Stiffness, and Blood Pressure in Dialysis Patients.

TypeinterventionalSponsorRegional Hospital HolstebroRan2011 to 2012Enrolled64ConditionsEnd-Stage Renal DiseaseArmsCholecalciferol, Placebo
3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 5 syntheses or guidelines pooled it, 61 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Review
  9. Vitamin D: are all compounds equal?Clinical kidney journal · 2025
    Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Vitamin D and Arterial Hypertension: Facts and Myths.Current hypertension reports · 2020
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Frank H MoseUniversity Clinic in Nephrology and Hypertension, Department of Medical Research and University of Aarhus, Holstebro Hospital, Holstebro, Denmark. frchri@rm.dk.
Henrik Vase
Thomas Larsen
Anne S P Kancir
Renata Kosierkiewic
Bartlomiej Jonczy
Annebirthe B Hansen
Anna E Oczachowska-Kulik
Ingrid M Thomsen
Jesper N Bech
Erling B Pedersen
Regional Hospital Holstebro · DKAarhus University Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients on chronic dialysis are at increased risk of vitamin D deficiency. In observational studies plasma 25-hydroxyvitamin D (p-25(OH) D) levels are inversely correlated with plasma BNP and adverse cardiovascular outcomes. Whether a causal relation exists has yet to be established. The aim of this study was to test the hypothesis that cholecalciferol supplementation improves cardiac function and reduces blood pressure (BP) and pulse wave velocity (PWV) in patients on chronic dialysis.

methodsIn a randomized, placebo-controlled, double-blind study, we investigated the effect of 75 μg (3000 IU) cholecalciferol daily for 6 months, in patients on chronic dialysis. We performed two-dimensional echocardiography, with doppler and tissue-doppler imaging, 24-h ambulatory BP (24-h BP), PWV, augmentation index (AIx), central BP (cBP) and brain natriuretic peptide (BNP) measurements at baseline and after 6 months.

resultsSixty-four patients were allocated to the study. Fifty dialysis patients with a mean age of 68 years (range: 46-88) and baseline p-25(OH) D of 28 (20;53) nmol/l completed the trial. Cholecalciferol increased left ventricular (LV) volume, but had no impact on other parameters regarding LV structure or left atrial structure. LV systolic function, LV diastolic function, PWV, cBP, AIx and BNP were not changed in placebo or cholecalciferol group at follow-up. 24-h BP decreased significantly in placebo group and tended to decrease in cholecalciferol group without any difference between treatments.

conclusionSix months of cholecalciferol treatment in patients on chronic dialysis did not improve 24-h BP, arterial stiffness or cardiac function.

trial registrationNCT01312714, Registration Date: March 9, 2011.

Indexed as

AgedBlood PressureCholecalciferolDouble-Blind MethodFemaleHeartHumansMaleMiddle AgedNatriuretic Peptide, BrainPlacebo EffectRenal DialysisRenal Insufficiency, ChronicTreatment OutcomeVitamin K DeficiencyVitaminsCholecalciferolNatriuretic Peptide, BrainVitamins

Identifiers

PMID24661355
PMCPMC3994388
OpenAlexW2026195740

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.